Viatris, Inc. (VTRS)
NASDAQ:VTRS
Top Page
Viatris
(NASDAQ:VTRS)
Select Model
Select Model
Rating:56Neutral
Price Target:
$13.50
▲(0.22% Upside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak profitability (deep 2025 losses and negative P/E) despite solid and stable cash flow. Technicals are supportive due to a strong uptrend, but momentum is overbought, limiting the technical score. Guidance and corporate actions (cost-savings program and Biocon stake sale) are constructive, though near-term margin pressure, manufacturing disruption risk, and sizable one-time restructuring costs temper the outlook.
Positive Factors
Strong cash generation
Consistent, positive operating and free cash flow across 2021–2025 provides durable financial flexibility. Persistent FCF supports debt service, dividend maintenance, buybacks and targeted BD, cushioning the firm during earnings volatility and enabling strategic deployment without immediate reliance on equity markets.
Negative Factors
Revenue decline & negative profitability
A multi-year revenue downtrend and a sharp swing to large net losses undermine shareholder equity and long-term earnings power. Sustained negative margins erode returns on capital, constrain reinvestment capacity and make the company reliant on cash flow and asset sales unless profitable growth is restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent, positive operating and free cash flow across 2021–2025 provides durable financial flexibility. Persistent FCF supports debt service, dividend maintenance, buybacks and targeted BD, cushioning the firm during earnings volatility and enabling strategic deployment without immediate reliance on equity markets.
Read all positive factors
Viatris (VTRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.51B
Dividend Yield3.99%
Average Volume (3M)9.64M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth-6.40%
EPS Growth-320.23%
CountryUS
Employees32,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.57
Shares Outstanding1,151,393,000
10 Day Avg. Volume7,173,283
30 Day Avg. Volume9,638,147
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-74.04
Forecast
1Y Price Target
$15.25Price Target Upside13.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.44
Revenue Forecast (FY)$14.62B
Viatris Business Overview & Revenue Model
Company Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, an...
How the Company Makes Money
Viatris makes money primarily by selling prescription and non-prescription medicines globally. Its revenue model is based on (1) high-volume sales of off-patent generic medicines and branded generics, where pricing and market share depend on compe...
Viatris Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyViatris Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call emphasized solid 2025 execution (revenue up ~2% operationally, adjusted EBITDA $4.2B), robust cash generation and a strengthened R&D pipeline with multiple regulatory milestones and late-stage programs. Management completed an enterprise strategic review targeting $650M gross savings ($400M net) with phased implementation and reinvestment to support growth. Near-term headwinds include an India facility shutdown (temporary), modest 2026 guidance (~2% revenue/EBITDA growth), margin pressure from LOEs and lower-margin mix, and one-time restructuring/transaction costs (~$700M range). Overall, the company presents a constructive, forward-looking plan with credible cash and pipeline catalysts, while acknowledging short-term execution and timing risks.Positive Updates
Full-Year Revenue and Profitability
Total 2025 revenues of $14.3B, representing ~2% growth versus 2024 on an operational/divestiture-adjusted basis; adjusted EBITDA of $4.2B and adjusted EPS of $2.35.
Negative Updates
India Manufacturing Disruption
A mid-February fire at the Nashik oral solid dose facility temporarily suspended manufacturing; restart expected beginning in April. Management baked <1% India recovery into 2026 guidance and previously faced a ~$325M headwind in 2025; FDA reinspection timing remains at agency discretion.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue and Profitability
Total 2025 revenues of $14.3B, representing ~2% growth versus 2024 on an operational/divestiture-adjusted basis; adjusted EBITDA of $4.2B and adjusted EPS of $2.35.
Read all positive updates
Company Guidance
Viatris guided 2026 to roughly 2% total revenue growth and ~2% adjusted EBITDA growth versus 2025 (a year in which it reported $14.3B in revenue, $4.2B adjusted EBITDA, $2.35 adjusted EPS and ~$2.2B free cash flow excluding transaction costs), and expects $450–$550M of new product revenues; regionally it anticipates developed markets +2%, Europe +4%, emerging markets +6%, Greater China +3% and North America flat (JANZ pressured by price regulation and a mid‑year Amitiza LOE), with gross margins modestly lower, adjusted SG&A down as a percent of sales, R&D flat and the $40M TSA benefit from 2025 not recurring. The company projects about $650M of gross cost savings from its strategic review over three years (phased ~30%/30%/40% in 2026–2028) with up to $250M reinvested for net savings of ~$400M and full run‑rate benefits by 2029, expects robust cash generation with >$2.5B available for deployment, will maintain the dividend, pursue accretive BD and some debt paydown to target ~2.8–3.2x gross leverage, and notes guidance is slightly back‑loaded (Q1 lowest for revenues, gross margin and FCF) and assumes <1% India recovery baked into the plan.Viatris Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
54
Neutral
Cash Flow
68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.30B | 14.74B | 15.43B | 16.26B | 17.89B |
| Gross Profit | 5.01B | 5.62B | 6.44B | 6.50B | 5.58B |
| EBITDA | -395.40M | 2.82B | 3.52B | 6.43B | 4.48B |
| Net Income | -3.51B | -634.20M | 54.70M | 2.08B | -1.27B |
Balance Sheet | |||||
| Total Assets | 37.19B | 41.50B | 47.69B | 50.02B | 54.84B |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 1.09B | 1.18B | 1.47B | 935.00M |
| Total Debt | 14.70B | 14.31B | 18.37B | 19.53B | 23.36B |
| Total Liabilities | 22.48B | 22.87B | 27.22B | 28.95B | 34.35B |
| Stockholders Equity | 14.71B | 18.64B | 20.47B | 21.07B | 20.49B |
Cash Flow | |||||
| Free Cash Flow | 1.94B | 1.98B | 2.33B | 2.51B | 2.51B |
| Operating Cash Flow | 2.32B | 2.30B | 2.80B | 3.00B | 3.02B |
| Investing Cash Flow | -427.70M | 1.80B | -764.10M | 1.47B | -117.80M |
| Financing Cash Flow | -1.29B | -4.33B | -2.30B | -3.88B | -3.01B |
Viatris Technical Analysis
Positive
13.47
Price Trends
14.27
Negative
13.00
Positive
11.32
Positive
Market Momentum
-0.19
Negative
46.27
Neutral
75.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTRS, the sentiment is Positive. The current price of 13.47 is above the 20-day moving average (MA) of 13.43, below the 50-day MA of 14.27, and above the 200-day MA of 11.32, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 46.27 is Neutral, neither overbought nor oversold. The STOCH value of 75.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTRS.
Viatris Risk Analysis
Viatris disclosed 51 risk factors in its most recent earnings report. Viatris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viatris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $10.84B | 21.72 | 16.00% | 0.64% | 10.63% | 6.35% | |
67 Neutral | $1.76B | 14.40 | 15.55% | ― | 48.87% | ― | |
61 Neutral | $36.88B | 25.43 | 20.09% | ― | -0.25% | ― | |
56 Neutral | $15.51B | -4.15 | -22.99% | 3.99% | -6.40% | -320.23% | |
54 Neutral | $3.95B | 54.80 | -67.91% | ― | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49B | -1.35 | -35.16% | 8.48% | -2.55% | 66.00% |
* Healthcare Sector Average
VTRS
Viatris
13.47
6.18
84.77%
RDY
Dr Reddy's Laboratories
13.31
0.13
0.96%
PRGO
Perrigo Company
10.86
-12.52
-53.55%
TEVA
Teva Pharmaceutical
30.82
17.22
126.62%
ANIP
ANI Pharmaceuticals
78.36
9.64
14.03%
AMRX
Amneal Pharmaceuticals
12.54
5.33
73.93%
Viatris Corporate Events
Business Operations and StrategyFinancial Disclosures
Viatris Launches Major Restructuring After Strong 2025 Results
Positive
Feb 26, 2026
On February 26, 2026, Viatris reported robust fourth-quarter 2025 revenues of $3.7 billion and full-year revenues of $14.3 billion, meeting or exceeding its 2025 financial guidance and returning more than $1 billion to shareholders, supported by s...
Executive/Board Changes
Viatris Announces Chief Legal Officer Transition and Successor
Neutral
Feb 3, 2026
On February 3, 2026, Viatris Inc. reported that Chief Legal Officer Brian Roman will step down from his role effective February 9, 2026, and remain with the company until April 1, 2026, to facilitate a transition, during which he will receive sepa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.